NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces today that the trial’s Independent Data Monitoring Committee (IDMC) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results